OSR Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OSR Health, Inc. on August 28, 2026, regarding events occurring on August 27, 2026. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Bellevue, WA. The report addresses a critical regulatory event concerning the listing status of its securities on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status events rather than financial performance data.
Material Changes and Events
- Nasdaq Hearing Scheduled: The Nasdaq Hearings Panel has scheduled a hearing for September 29, 2026, at 10:00 a.m. Eastern Time.
- Trading Suspension: Trading in the Company's securities (Common Stock "OSRH" and Redeemable Warrants "OSRHW") was suspended effective August 26, 2026.
- Delisting Status: While the hearing request did not stay the trading suspension, it successfully stayed the filing of a Form 25-NSE, which would have resulted in formal delisting pending the Panel's decision.
- Appeal Filed: The Company submitted a hearing request on August 25, 2026, appealing the Staff's delisting determination.
Outlook, Risks, and Management Commentary
Management intends to present a comprehensive plan to regain and sustain compliance with Nasdaq's continued listing requirements during the September 29 hearing. The Company will advocate vigorously for the continued listing of its securities. However, the filing explicitly states there can be no assurance that the Panel will grant the request for continued listing or that the Company will regain compliance. The report includes standard forward-looking statement disclaimers regarding the uncertainty of the hearing outcome and the potential for formal delisting.
Key Facts for Investor Verification
- Verify the outcome of the Nasdaq Hearings Panel decision scheduled for September 29, 2026.
- Confirm whether the Company successfully regains compliance with Nasdaq listing requirements to resume trading.
- Monitor for the potential filing of a Form 25-NSE if the hearing request is denied.
- Review the specific compliance plan the Company intends to present to the Panel.